Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies

K. Itoh, Charles M. Balch, J. L. Murray, D. R. Parkinson, A. B. Markowitz, M. Talpaz, K. Lee, A. A. Zukiwski, M. I. Ross, S. S. Legha, K. Hayakawa, M. A. Salmeron, L. B. Augustus

Research output: Contribution to journalArticle

Abstract

Immunological properties of melanoma TILs before and/or after IL-2-based biotherapies were investigated. TILs harvested before therapies, including those for adoptive transfer, proliferated well in culture with IL-2 and displayed cytotoxicity relatively restricted to autologous tumor cells. In contrast, TILs during or at the end of IL-2 based therapies did not proliferate in culture with IL-2. TILs from tumors even harvested 45 days after the end of IL-2 therapy modestly proliferated in culture with IL-2 and showed MHC-nonrestricted cytotoxicity. The number of live tumor cells that were yielded from melanomas during or at the end of IL-2-based therapies significantly decreased in all nine patients with metastatic melanomas, regardless of their clinical responses (2 PR, 2 MR, 2 SD, and 3 PD). Collectively, these results suggest that current IL-2-based therapies rsulted in both transient nonresponsiveness of TILs to Il-2 and transient decrease in the number of live tumour cells in most melanoma patients.

Original languageEnglish (US)
Pages (from-to)647-654
Number of pages8
JournalIn vivo (Athens, Greece)
Volume5
Issue number6
StatePublished - 1991
Externally publishedYes

Fingerprint

Tumor-Infiltrating Lymphocytes
Biological Therapy
Lymphocytes
Interleukin-2
Tumors
Melanoma
Cells
Cytotoxicity
Cell culture
Neoplasms
Therapeutics
Adoptive Transfer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Itoh, K., Balch, C. M., Murray, J. L., Parkinson, D. R., Markowitz, A. B., Talpaz, M., ... Augustus, L. B. (1991). Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. In vivo (Athens, Greece), 5(6), 647-654.

Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. / Itoh, K.; Balch, Charles M.; Murray, J. L.; Parkinson, D. R.; Markowitz, A. B.; Talpaz, M.; Lee, K.; Zukiwski, A. A.; Ross, M. I.; Legha, S. S.; Hayakawa, K.; Salmeron, M. A.; Augustus, L. B.

In: In vivo (Athens, Greece), Vol. 5, No. 6, 1991, p. 647-654.

Research output: Contribution to journalArticle

Itoh, K, Balch, CM, Murray, JL, Parkinson, DR, Markowitz, AB, Talpaz, M, Lee, K, Zukiwski, AA, Ross, MI, Legha, SS, Hayakawa, K, Salmeron, MA & Augustus, LB 1991, 'Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies', In vivo (Athens, Greece), vol. 5, no. 6, pp. 647-654.
Itoh, K. ; Balch, Charles M. ; Murray, J. L. ; Parkinson, D. R. ; Markowitz, A. B. ; Talpaz, M. ; Lee, K. ; Zukiwski, A. A. ; Ross, M. I. ; Legha, S. S. ; Hayakawa, K. ; Salmeron, M. A. ; Augustus, L. B. / Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. In: In vivo (Athens, Greece). 1991 ; Vol. 5, No. 6. pp. 647-654.
@article{70eb020722e34039b47c20fff696205e,
title = "Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies",
abstract = "Immunological properties of melanoma TILs before and/or after IL-2-based biotherapies were investigated. TILs harvested before therapies, including those for adoptive transfer, proliferated well in culture with IL-2 and displayed cytotoxicity relatively restricted to autologous tumor cells. In contrast, TILs during or at the end of IL-2 based therapies did not proliferate in culture with IL-2. TILs from tumors even harvested 45 days after the end of IL-2 therapy modestly proliferated in culture with IL-2 and showed MHC-nonrestricted cytotoxicity. The number of live tumor cells that were yielded from melanomas during or at the end of IL-2-based therapies significantly decreased in all nine patients with metastatic melanomas, regardless of their clinical responses (2 PR, 2 MR, 2 SD, and 3 PD). Collectively, these results suggest that current IL-2-based therapies rsulted in both transient nonresponsiveness of TILs to Il-2 and transient decrease in the number of live tumour cells in most melanoma patients.",
author = "K. Itoh and Balch, {Charles M.} and Murray, {J. L.} and Parkinson, {D. R.} and Markowitz, {A. B.} and M. Talpaz and K. Lee and Zukiwski, {A. A.} and Ross, {M. I.} and Legha, {S. S.} and K. Hayakawa and Salmeron, {M. A.} and Augustus, {L. B.}",
year = "1991",
language = "English (US)",
volume = "5",
pages = "647--654",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies

AU - Itoh, K.

AU - Balch, Charles M.

AU - Murray, J. L.

AU - Parkinson, D. R.

AU - Markowitz, A. B.

AU - Talpaz, M.

AU - Lee, K.

AU - Zukiwski, A. A.

AU - Ross, M. I.

AU - Legha, S. S.

AU - Hayakawa, K.

AU - Salmeron, M. A.

AU - Augustus, L. B.

PY - 1991

Y1 - 1991

N2 - Immunological properties of melanoma TILs before and/or after IL-2-based biotherapies were investigated. TILs harvested before therapies, including those for adoptive transfer, proliferated well in culture with IL-2 and displayed cytotoxicity relatively restricted to autologous tumor cells. In contrast, TILs during or at the end of IL-2 based therapies did not proliferate in culture with IL-2. TILs from tumors even harvested 45 days after the end of IL-2 therapy modestly proliferated in culture with IL-2 and showed MHC-nonrestricted cytotoxicity. The number of live tumor cells that were yielded from melanomas during or at the end of IL-2-based therapies significantly decreased in all nine patients with metastatic melanomas, regardless of their clinical responses (2 PR, 2 MR, 2 SD, and 3 PD). Collectively, these results suggest that current IL-2-based therapies rsulted in both transient nonresponsiveness of TILs to Il-2 and transient decrease in the number of live tumour cells in most melanoma patients.

AB - Immunological properties of melanoma TILs before and/or after IL-2-based biotherapies were investigated. TILs harvested before therapies, including those for adoptive transfer, proliferated well in culture with IL-2 and displayed cytotoxicity relatively restricted to autologous tumor cells. In contrast, TILs during or at the end of IL-2 based therapies did not proliferate in culture with IL-2. TILs from tumors even harvested 45 days after the end of IL-2 therapy modestly proliferated in culture with IL-2 and showed MHC-nonrestricted cytotoxicity. The number of live tumor cells that were yielded from melanomas during or at the end of IL-2-based therapies significantly decreased in all nine patients with metastatic melanomas, regardless of their clinical responses (2 PR, 2 MR, 2 SD, and 3 PD). Collectively, these results suggest that current IL-2-based therapies rsulted in both transient nonresponsiveness of TILs to Il-2 and transient decrease in the number of live tumour cells in most melanoma patients.

UR - http://www.scopus.com/inward/record.url?scp=0026321309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026321309&partnerID=8YFLogxK

M3 - Article

C2 - 1810451

AN - SCOPUS:0026321309

VL - 5

SP - 647

EP - 654

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 6

ER -